Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia.
Tabchi S, Nair R, Kunacheewa C, Patel KK, Lee HC, Thomas SK, Amini B, Ahmed S, Mehta RS, Bashir Q, Qazilbash MH, Weber DM, Orlowski RZ, Alexanian R, Feng L, Manasanch EE. Tabchi S, et al. Among authors: kunacheewa c. Clin Lymphoma Myeloma Leuk. 2019 Sep;19(9):560-569. doi: 10.1016/j.clml.2019.05.001. Epub 2019 May 17. Clin Lymphoma Myeloma Leuk. 2019. PMID: 31201134 Free PMC article. Review.
Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study.
Kunacheewa C, Lee HC, Patel K, Thomas S, Amini B, Srour S, Bashir Q, Nieto Y, Qazilbash MH, Weber DM, Feng L, Orlowski RZ, Lin P, Manasanch EE. Kunacheewa C, et al. Clin Lymphoma Myeloma Leuk. 2020 May;20(5):e221-e238. doi: 10.1016/j.clml.2020.01.001. Epub 2020 Jan 15. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32037287 Free PMC article. Clinical Trial.
Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy.
Kunacheewa C, Feng L, Manasanch EE, Bashir Q, Patel KK, Mehta R, Kaufman GP, Srour S, Saini N, Iyer SP, Thomas SK, Weber DM, Orlowski RZ, Qazilbash MH, Lee HC. Kunacheewa C, et al. Br J Haematol. 2021 May;193(3):e23-e26. doi: 10.1111/bjh.17393. Epub 2021 Mar 21. Br J Haematol. 2021. PMID: 33748943 No abstract available.
Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapies.
Manasanch EE, Berrios D, Fountain E, Claussen CM, Chuang T, Kaufman G, Amini B, Bashir Q, Nieto Y, Qazilbash M, Patel K, Thomas SK, Weber DM, Berkova Z, Toruner G, Lin P, Feng L, Lee HC, Orlowski RZ, Kunacheewa C. Manasanch EE, et al. Among authors: kunacheewa c. Br J Haematol. 2021 Feb;192(4):e115-e120. doi: 10.1111/bjh.17344. Epub 2021 Jan 24. Br J Haematol. 2021. PMID: 33486754 No abstract available.
Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow up.
Manasanch EE, Kunacheewa C, Claussen CM, Lee HC, Thomas SK, Gunther J, Pinnix CC, Dabaja BS, Amini B, Alexanian R, Orlowski RZ, Dong W, Feng L, Weber DM. Manasanch EE, et al. Among authors: kunacheewa c. Blood Cancer J. 2021 Feb 8;11(2):17. doi: 10.1038/s41408-021-00419-1. Blood Cancer J. 2021. PMID: 33563896 Free PMC article. No abstract available.
New Drugs in Multiple Myeloma.
Kunacheewa C, Orlowski RZ. Kunacheewa C, et al. Annu Rev Med. 2019 Jan 27;70:521-547. doi: 10.1146/annurev-med-112017-091045. Annu Rev Med. 2019. PMID: 30691369 Review.
18 results